Armata Pharmaceuticals is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. Their facility is equipped for product development with capabilities spanning from bench to clinic. Armata is dedicated to the discovery of natural phages, complemented by a team of scientists that harness the natural power and diversity of these phages through synthetic biology and engineering. In-house formulation development allows tailoring of the drug product to an indication, and Armata’s GMP drug manufacturing suites enable the production, purification, testing, and release of clinical trial material.
Bacteriophage product pipeline:
- Phage Product Candidate target: Pseudomonas aeruginosa for Respiratory infections (AP-PA02)
- Phage Product Candidate target: Staphylococcus aureus (AP-SA02)